Page last updated: 2024-11-12

vosaroxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vosaroxin: has antineoplastic activity; vosaroxin was formerly voreloxin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9952884
CHEMBL ID68117
SCHEMBL ID674441
MeSH IDM0465916

Synonyms (52)

Synonym
HY-10534
vosaroxin
spc-595
ag-7352
sns-595
CHEMBL68117
voreloxin
D08024
175414-77-4
vosaroxin (usan)
quinprezo
(+)-ag-7352
ag 7352
unii-k6a90iiz19
k6a90iiz19 ,
1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(3-methoxy-4-(methylamino)-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-, (3s-trans)-
sns 595
vosaroxin [usan:inn]
ag7352
1,4-dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
spc 595
CS-0790
(+)-7-((3s,4s)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
vosaroxin [usan]
1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-7-((3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-
vosaroxin [inn]
vosaroxin [who-dd]
vosaroxin [mart.]
SCHEMBL674441
7-((3s,4s)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
J-690243
EX-A847
voreloxin;sns-595;ag 7352
AKOS030526660
7-[(3s,4s)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
mfcd13185156
vosaroxin hydrochloride, >=98% (hplc)
SW219924-1
DB11999
7-((3s,4s)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid.
DTXSID50938662
Q18395775
sns-595;vosaroxin;ag 7352
960398-99-6
trans-7-(3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
174726-60-4
A911613
7-[(3s,4s)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid
nsc-760764
nsc760764
1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-
AC-36005

Research Excerpts

Overview

Vosaroxin is a first-in-class anticancer quinolone derivative topoisomerase II inhibitor. It is currently in development in combination with cytarabine for the treatment of acute myeloid leukemia (AML)

ExcerptReferenceRelevance
"Vosaroxin is a quinolone-derivative anticancer agent with inhibitory activity on type II DNA topoisomerases (TOP2). "( Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.
Yu, CZ; Zhao, XL, 2018
)
3.37
"Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. "( A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK, 2015
)
2.17
"Vosaroxin is a first-in-class anti-cancer quinolone that inhibits topoisomerase-II leading to cell cycle arrest and apoptosis. "( Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski, AK; Lewis, ID; Ross, DM, 2015
)
3.3
"Vosaroxin is a promising new agent in the treatment of AML, with the potential to improve CR rates in a high-risk group of patients with relapsed and refractory AML. "( Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski, AK; Lewis, ID; Ross, DM, 2015
)
3.3
"Vosaroxin is a first-in-class anticancer quinolone derivative that has shown promising activity in patients with relapsed or refractory AML."( The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Ravandi, F; Short, NJ, 2016
)
1.45
"Vosaroxin is a first-in-class anticancer quinolone derivative topoisomerase II inhibitor that is currently in development in combination with cytarabine for the treatment of acute myeloid leukemia (AML). "( Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry.
Beijnen, JH; Fox, JA; Jamieson, G; Lucas, L; Nijenhuis, CM; Rosing, H; Schellens, JH, 2016
)
2.21
"Vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. "( Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Fox, JA; Jamieson, GC; Poi, M; Strickland, SA, 2016
)
2.11
"Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. "( Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton, CB; Ravandi, F, 2017
)
2.15
"Vosaroxin is a first in class naphthyridine analog structurally related to quinolone antibacterials, that intercalates DNA and inhibits topoisomerase II. "( Radiosensitization by the novel DNA intercalating agent vosaroxin.
Camphausen, K; Gordon, IK; Graves, C; Kil, WJ; Kramp, T; Tofilon, P, 2012
)
2.07

Effects

Vosaroxin has shown efficacy as a novel cytotoxic agent. Despite a similar mechanism of action has significant advantages over anthracyclines. As vosar toxin has been associated with increased toxicity in some studies, appropriate dosing and patient selection will be crucial.

ExcerptReferenceRelevance
"Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. "( Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Freeman, C; Giles, F; Keane, N; Swords, R, 2013
)
3.28
"As vosaroxin has been associated with increased toxicity in some studies, appropriate dosing and patient selection will be crucial to determine the future role of vosaroxin in AML."( The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Ravandi, F; Short, NJ, 2016
)
1.25

Compound-Compound Interactions

ExcerptReferenceRelevance
" Escalating vosaroxin doses (10-minute infusion; 10-90 mg/m(2); days 1, 4) were given in combination with cytarabine on one of two schedules: schedule A (24-hour continuous intravenous infusion, 400 mg/m(2)/day, days 1-5) or schedule B (2-hour intravenous infusion, 1 g/m(2)/day, days 1-5)."( A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK, 2015
)
1.11

Dosage Studied

ExcerptRelevanceReference
" Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11)."( A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Allen, RS; Chen, T; Cripe, LD; Fox, JA; Giles, FJ; Kantarjian, HM; Karp, JE; Lancet, JE; List, AF; Michelson, GC; Ravandi, F; Ricklis, RM, 2011
)
0.69
" As vosaroxin has been associated with increased toxicity in some studies, appropriate dosing and patient selection will be crucial to determine the future role of vosaroxin in AML."( The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Ravandi, F; Short, NJ, 2016
)
1.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency6.73590.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency6.73590.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID154605Cytotoxic activity against human tumor PANC-1 pancreas cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID200760Cytotoxic activity against human tumor SCaBER bladder cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID91033Cytotoxic activity against human tumor Hs 746.T stomach cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID82503Cytotoxic activity against human tumor HL-60 leukemia cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID202499Cytotoxic activity against human tumor SK-OV-3 ovary cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID200422Cytotoxic activity against human tumor SBC-3 lung cells2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (10.26)29.6817
2010's32 (82.05)24.3611
2020's3 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.47 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index1.85 (0.95)

This Compound (30.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (23.08%)5.53%
Reviews11 (28.21%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (48.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]